Study identifier:SD-004-0377
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Once daily administration of 200 µg budesonide Turbuhaler and 200 µg fluticasone propionate via Diskus inhaler in stable asthmatics.
asthma
Phase 4
-
-
-
-
Interventional
-
Allocation: - 
Endpoint Classification: - 
Intervention Model: - 
Masking: - 
Primary Purpose: - 
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|